Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

• Egile Nagusiak: Egle Stukaite-Ruibiene (Egilea), Rimvydas Norvilas (Egilea), Vaidas Dirse (Egilea), Sigita Stankeviciene (Egilea), Goda Elizabeta Vaitkeviciene (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI). NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemi...